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Effect of Telmisartan on Functional Outcome, Recurrence,
and Blood Pressure in Patients With Acute Mild
Ischemic Stroke
A PRoFESS Subgroup Analysis
Philip M. W. Bath, MD, FRCP; Renee´ H. Martin, PhD; Yuko Palesch, PhD; Daniel Cotton, MS;
Salim Yusuf, MB, BS, DPhil; Ralph Sacco, MD; Hans-Christoph Diener, MD, PhD; Danilo Toni, MD;
Conrado Estol, MD, PhD; Robin Roberts, MSc; for the PRoFESS Study Group
Background and Purpose—High blood pressure (BP) is common in acute ischemic stroke and associated independently
with a poor functional outcome. However, the management of BP acutely remains unclear because no large trials have
been completed.
Methods—The factorial PRoFESS secondary stroke prevention trial assessed BP-lowering and antiplatelet strategies in
20 332 patients; 1360 were enrolled within 72 hours of ischemic stroke, with telmisartan (angiotensin receptor
antagonist, 80 mg/d, n647) vs placebo (n713). For this nonprespecified subgroup analysis, the primary outcome was
functional outcome at 30 days; secondary outcomes included death, recurrence, and hemodynamic measures at up to 90
days. Analyses were adjusted for baseline prognostic variables and antiplatelet assignment.
Results—Patients were representative of the whole trial (age 67 years, male 65%, baseline BP 147/84 mm Hg, small artery
disease 60%, NIHSS 3) and baseline variables were similar between treatment groups. The mean time from stroke to
recruitment was 58 hours. Combined death or dependency (modified Rankin scale: OR, 1.03; 95% CI, 0.84–1.26; P0.81;
death: OR, 1.05; 95% CI, 0.27–4.04; and stroke recurrence: OR, 1.40; 95% CI, 0.68–2.89; P0.36) did not differ between the
treatment groups. In comparison with placebo, telmisartan lowered BP (141/82 vs 135/78 mm Hg, difference 6 to 7 mm Hg and 2
to 4 mm Hg; P0.001), pulse pressure (3 to 4 mm Hg; P0.002), and rate-pressure product (466 mm Hg.bpm; P0.0004).
Conclusion—Treatment with telmisartan in 1360 patients with acute mild ischemic stroke and mildly elevated BP appeared
to be safe with no excess in adverse events, was not associated with a significant effect on functional dependency, death,
or recurrence, and modestly lowered BP. (Stroke. 2009;40:3541-3546.)
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High blood pressure (BP) is present in 70% to 80% ofpatients with acute ischemic stroke6,7 and is associated
independently with a poor outcome.7–10 However, there is a
reluctance to lower a high BP because ischemic stroke is
associated with focal attenuation of cerebral autoregulation.
As a result, there is equipoise in whether high BP should be
lowered (epidemiological evidence) or not (pathophysiolog-
ical concerns).
Previous data on the effects of BP lowering on functional
outcome in acute stroke are sparse and have given conflicting
results. Trials of calcium channel blockers were ineffective
overall,11 and some studies reported then to be hazardous.12,13
The -receptor antagonists were associated with a worse
outcome in 1 trial.14 The ACCESS trial found that treatment
with oral candesartan (angiotensin receptor antagonist
[ARA]) was associated with reduced recurrent vascular
events at 1 year (secondary outcome) but had no effect on
functional outcome at 3 months (primary outcome) or BP
over the course of the first 7 days of treatment.15 A small trial
of lisinopril or labetalol vs placebo suggested that case
fatality (secondary outcome) was reduced in patients receiv-
ing antihypertensive therapy, although there was no effect on
functional outcome (primary outcome).16 Few studies have
assessed the effect of antihypertensive agents on cerebral
blood flow (CBF),17 although some agents, eg, nitrates, are able
to lower BP without adversely altering cerebral blood flow.18
Nevertheless, all of these studies enrolled 400 patients and no
large trials have been completed in patients with acute ischemic
stroke.
The Prevention Regimen for Effectively Avoiding Second
Strokes (PRoFESS) trial is the largest secondary stroke
prevention study and compared, in a factorial design, telmis-
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artan (ARA) with placebo, and aspirin-extended release
dipyridamole with clopidogrel, in preventing recurrent
stroke.19 A key intention of the protocol was to recruit the
patient at a time when the risk of recurrence was particularly
high;19 39.9% patients were recruited within 10 days of the
index event.2 Also, 1360 (6.7%) of patients were recruited
within 72 hours of stroke onset, thereby providing the
opportunity to assess, in a randomized design, the safety and
efficacy of lowering blood pressure with telmisartan (on top
of standard poststroke antihypertensive treatment) in patients
with acute ischemic stroke.
Materials and Methods
The PRoFESS trial protocol19 and primary results1,2 have been
published. Briefly, PRoFESS compared the effect of lowering BP
with telmisartan (ARA, 80 mg daily) vs placebo, and combined
aspirin (25 mg twice daily) and extended release dipyridamole (200
mg twice daily) vs clopidogrel (75 mg daily), in a 22 factorial
design, in patients with recent ischemic stroke. Over 34 months,
20 332 patients were randomized from 695 centers in 35 countries
and followed-up for a mean duration of 30 months. All patients
received best medical care independent of treatment assignment; in
particular, the PRoFESS study protocol mandated that all patients
with hypertension should be treated with an appropriate BP-lowering
medication, excluding an ARA, with a target blood pressure of
140/90 mm Hg.
Inclusion Criteria
The aim of this PRoFESS subgroup analysis, which was not
prespecified in the statistical analysis plan, was to assess the safety
and efficacy of lowering BP with telmisartan in patients with acute
stroke. Patients were included if they were enrolled in the main trial
and had been randomized within 72 hours of stroke onset. The time
of 72 hours was chosen a priori to mirror the design of the ACCESS
trial of candesartan, another ARA.15 Some PRoFESS inclusion
criteria are relevant specifically to assessment of BP management in
acute stroke: ischemic stroke; symptoms persisting for24 hours, or
if 24 hours then CT or MRI evidence of a new stroke; hospital-
ization; age older than 55 years, or age 50 to 54 years if 2 additional
vascular risk factors present; seated systolic BP (SBP) 121 to
180 mm Hg; seated diastolic BP 110 mm Hg; and neurologically
stable. Similarly, relevant key exclusion criteria are: dysphagia
preventing oral medication; severe dependency at time of random-
ization (modified Rankin Scale [mRS] 3); currently using or
needing ARA; known severe renal insufficiency or renal artery
stenosis; hyperkalemia; uncorrected volume or sodium depletion;
known severe coronary artery disease or recent MI; and patients
scheduled for carotid endarterectomy.
Hemodynamic Measures
SBP, diastolic BP, and heart rate (HR) were measured using a
validated semiautomatic monitor (Omron 705CP).20 Other hemody-
namic variables were derived mathematically from BP and HR:
Pulse pressureSBPdiastolic BP
SBP variabilitySD of SBP/mean SBP
Rate pressure product (measure of cardiac work)SBPHR
Outcomes
The primary outcome in this post hoc subgroup analysis was
functional outcome measured using the mRS at 30 days after
randomization; a more conventional trial time of 90 days was not
possible because mRS was not measured at this point. Secondary
outcomes were studied at 7, 30, and 90 days (thereby mimicking the
design of many acute stroke trials) and included hemorrhagic
transformation of the infarct, cerebral edema, recurrent stroke, MI,
composite vascular events (vascular death, nonfatal stroke, or MI),
death, and serious adverse events. When possible, ordered categor-
ical outcomes were analyzed using ordinal statistical approaches.21,22
Tolerability was measured by adherence to therapy.
Analyses
Data are shown as the number of subjects (%) or mean (SD).
Comparisons were performed with binary logistic regression (dichot-
omous data), ordinal logistic regression, or the Mann–Whitney U test
(ordered categorical data), or multiple regression (continuous data).
Statistical models were adjusted for prognostic covariates: baseline
age, sex, severity, and SBP, and antiplatelet treatment assignment
(aspirin/dipyridamole vs clopidogrel). OR (95% CI) are shown and
statistical significance was set at P0.05. Analyses were performed
using SAS version 9.1.
Results
This subgroup analysis of the PRoFESS trial1,2 examined the
clinical usefulness of adding telmisartan vs placebo to stan-
dard poststroke antihypertensive treatment in 1360 patients
(telmisartan 647, placebo 713) recruited within 72 hours of
stroke onset (supplemental Figure I, available online at http://
stroke.ahajournals.org). The mean time from stroke to recruit-
ment was 58 hours, with the majority of patients recruited during
the third day after stroke onset; treatment was started within 3
days of stroke in 853 patients (63%) and within 4 days in 1250
(92%). The characteristics of patients in this analysis were
broadly similar to those of the whole trial (Table 1). The mean
baseline BP was 147/84 mm Hg, and severity was mild with
NIHSS3. The treatment groups were similar for demographic,
clinical, and hemodynamic measures (Table 1).
BP
In comparison with placebo, telmisartan lowered BP signifi-
cantly by 6 to 7 mm Hg and 2 to 4 mm Hg over the 90 days
(Table 2). Parallel reductions in pulse pressure and rate-pressure
product were present. No effect on heart rate was seen.
Outcome
Combined death or dependency (mRS at 30 days after
randomization, with adjustment for baseline covariates) did
not differ whether analyzed as an ordinal outcome (ordered
mRS categories: 0, 1, 2, 3, 4–6 to maintain proportionality)21
(OR, 1.03; 95% CI, 0.84–1.26; P0.81; Figure 1) or with
dichotomization of the data at the median (mRS 0–1 vs 2–6;
OR, 1.00; 95% CI, 0.77–1.29; Table 3). No subgroups
showed differential treatment effects (supplemental Figure II,
available online at http://stroke.ahajournals.org).
The distribution of ordinal stroke events (fatal, dependent
[mRS 2–5], independent [mRS 0,1], TIA, none)22 did not
differ between the treatment groups (Mann–Whitney U test,
P0.42; Figure 2). Similarly, the time to recurrence did not
differ between the treatment groups (log-rank test, P0.40).
Similarly, other events (ie, death, stroke recurrence, MI, and
combined vascular events) did not differ between the treatment
groups, whether measured at 7, 30, or 90 days (Table 3). There
was no difference in the Mini-Mental State Examination at 30
days.
Serious Adverse Events
Serious adverse events were similar between telmisartan and
control (Table 3; fatal, 5 vs 6; nonfatal, 45 vs 33). Selected
serious adverse events relevant to stroke, BP-lowering, or
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Table 1. Patient Characteristics at Enrollment
Characteristic Telmisartan (N647) Placebo (N713) All Trial
Demographics
Age, yr (SD) 66.8 (8.8) 67.1 (9.2) 66.1 (8.6)
Male (%) 420 (64.9) 464 (65.1) 13 022 (64.0)
Ethnicity (%)
White 369 (57.0) 407 (57.0) 11 697 (57.5)
Asian 221 (34.2) 240 (33.7) 6660 (32.8)
Black 38 (5.9) 41 (5.8) 816 (4.0)
Other 19 (2.9) 25 (3.5) 1159 (5.7)
Clinical history
Previous stroke/TIA (%) 160 (24.7) 184 (25.8) 4997 (24.6)
Atrial fibrillation (%) 10 (1.6) 14 (2.0) 540 (2.7)
Hypertension (%) 453 (70.0) 503 (70.6) 15 048 (74.0)
Hypertension, treated (%) 345 (53.3) 383 (53.7) 12 231 (60.1)
Diabetes mellitus (%) 176 (27.2) 198 (27.8) 5743 (28.3)
Hyperlipidemia (%) 264 (40.8) 283 (39.7) 9493 (46.7)
Left ventricular hypertrophy (%) 79 (12.5) 80 (11.6) 3167 (16.3)
Ischemic heart disease (%) 95 (14.7) 104 (14.6) 3304 (16.3)
Smoker, current (%) 158 (24.4) 178 (25.0) 4308 (21.2)
Antihypertensives (%)
Angiotensin-converting enzyme inhibitor 204 (31.5) 206 (28.9) 7,519 (37.0)
Angiotensin receptor antagonist 20 (3.1) 24 (3.4) 1,059 (5.2)
Alpha-receptor antagonist 14 (2.2) 14 (2.0) 432 (2.1)
Beta-receptor antagonist 134 (20.7) 141 (19.8) 4231 (20.8)
Calcium channel blocker 113 (17.5) 166 (23.3) 4960 (24.4)
Diuretic 120 (18.6) 131 (18.4) 4261 (21.0)
Potassium sparing diuretic 13 (2.0) 10 (1.4) 307 (1.5)
Time from stroke, day 2.4 (0.7) 2.4 (0.7) 26.9 (27.3)
0–1 73 (11.3) 99 (13.9) …
1–2 239 (36.9) 257 (36.0) …
2–3 335 (51.8) 357 (50.1) …
Clinical details
BP, mm Hg (SD)
Systolic 146 (16.2) 147 (16.3) 144 (16.6)
Diastolic 84 (10.1) 84 (10.2) 84 (10.5)
Pulse pressure 62.4 (14.2) 63.1 (14.7) 60.3 (13.9)
Heart rate, bpm 72.8 (11.9) 73.1 (11.4) 73.2 (11.7)
Rate-pressure product, mm Hg.bpm 10 637 (2008) 10 747 (2028) 10 540 (2052)
Body mass index, kg.m2 (SD) 26.9 (4.9) 26.8 (4.6) 26.8 (5.0)
TOAST classification (%)
Large-artery atherosclerosis 129 (19.9) 156 (21.9) 5805 (28.6)
Cardioembolism 11 (1.7) 7 (1.0) 369 (1.8)
Small-artery occlusion 402 (62.1) 406 (56.9) 10 578 (52.0)
Other determined etiology 14 (2.2) 9 (1.3) 416 (2.1)
Undetermined etiology 91 (14.1) 135 (18.9) 3148 (15.5)
Missing … … 16 (0.1)
mRS (%)
0 (no symptoms) 74 (11.4) 83 (11.6) 2853 (14.0)
1 (no significant disability) 219 (33.9) 279 (39.1) 7580 (37.3)
2 (slight disability) 182 (28.1) 191 (26.8) 5081 (25.0)
3 (moderate disability) 109 (16.9) 91 (12.8) 2891 (14.2)
4 (moderately severe disability) 63 (9.7) 69 (9.7) 1926 (9.5)
NIH Stroke Scale (SD) 2.9 (2.8) 3.1 (2.9) 2.8 (2.9)
Data for the whole trial are given for comparison. N (%) or mean (SD).
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treatment (telmisartan, placebo) included: hypotension (2 vs
2), syncope (1 vs 1), and falls (2 vs 1). No serious adverse
events related to edema extension, cerebral hemorrhage, MI,
or hyperkalemia were recorded over the 90 days.
Discussion
The aim of the present nonprespecified subgroup analysis
was to investigate the safety, efficacy, and tolerability of
telmisartan when started in the acute phase of an ischemic
stroke; 1360 patients were randomized within 72 hours of the
onset of ischemia and data for these subjects form the basis of
this report. In comparison with placebo, telmisartan did not
alter functional outcome (assessed using the mRS) at 30 days
or other outcomes, including stroke recurrence, MI, compos-
ite vascular outcome, or death, each at 90 days. Hence, these
results mirror those seen across the main study, this being
neutral, such that adding telmisartan to standard poststroke
treatment did not reduce stroke recurrence at an average of 2.5
years in comparison with placebo.1 Despite the fact that BP at
baseline was reasonably well controlled (mean, 147/84 mm Hg),
telmisartan further reduced it by 6 to 7 mm Hg and 2 to
4 mm Hg over the first 90 days after stroke; parallel reductions
in pulse pressure and rate-pressure product were also seen.
Although telmisartan did not alter stroke recurrence in
either this subgroup analysis or across the whole trial,1 it is
noteworthy that the direction of the point estimates were in
opposite directions. In the main trial, a trend to reduction was
apparent (HR, 0.95; 95% CI, 0.86–1.04; P0.23); a post hoc
analysis indicated that recurrence was nonsignificantly higher
with telmisartan during the first 6 months of treatment (HR,
1.07; 95% CI, 0.92–1.25) and significantly lower thereafter
(HR, 0.88; 95% CI, 0.78–0.99), with a significant treatment
by time interaction (P0.042).1 As with short-term treatment
in the main trial, a nonsignificant increase in the odds of
Table 2. Hemodynamic Effects on Treatment at Days 7, 30, and 90 After Enrollment
Telmisartan (n647) Placebo (n713) Difference (95% CI) P
Day 7
Subjects (%) 479 (74.0) 542 (76.0) … …
SBP, mm Hg 135.3 (17.8) 141.4 (17.0) 6.1 (4.0, 8.2) 0.0001
Diastolic BP, mm Hg 78.4 (10.8) 81.6 (11.0) 3.2 (1.8, 4.5) 0.0001
Pulse pressure, mm Hg 56.8 (14.7) 59.7 (14.7) 2.9 (1.1, 4.7) 0.0017
Heart rate, bpm 74.3 (11.1) 74.2 (10.8) 0.2 (1.5, 1.2) 0.82
Rate-pressure product (SBP.HR) 10057 (1937) 10523 (2070) 466 (210, 723) 0.0004
Day 30
Subjects (%) 612 (94.6) 674 (94.5) … …
N of nontrial antihypertensives (mean) 0.96 (1.03) 1.04 (1.03) 0.08 (0.99, 1.07) 0.14
0 (%) 271 (41.9) 267 (37.5) … …
1 203 (31.4) 231 (32.4) … …
2 117 (18.1) 151 (21.2) … …
3 42 (6.50 50 (7.0) … …
4 14 (2.2) 12 (1.7) … …
5 0 (0) 2 (0.3) … …
SBP, mm Hg 135.7 (20.0) 142.6 (18.6) 6.9 (4.8, 9.0) 0.0001
Diastolic BP, mm Hg 79.6 (11.9) 83.1 (11.2) 3.6 (2.3, 4.8) 0.0001
Pulse pressure, mm Hg 56.2 (15.1) 59.5 (14.9) 3.3 (1.7, 5.0) 0.0001
Day 90
Subjects (%) 592 (91.5) 664 (93.1) … …
SBP, mm Hg 134.5 (19.9) 140.3 (19.0) 5.8 (3.6, 8.0)) 0.0001
Diastolic BP, mm Hg 79.2 (11.1) 81.5 (11.2) 2.4 (1.1, 3.6) 0.0002
Pulse pressure, mm Hg 55.3 (15.4) 58.7 (15.9) 3.5 (1.7, 5.2) 0.0001
N (%) or mean (SD) with difference (95% CI). Comparisons by 2 test or t test.
Figure 1. The mRS at day 30, comparison by Mann–Whitney U,
P0.55 (note: mRS0, no symptoms; mRS1, symptoms;
mRS2, slight disability but independent; mRS3, moderate
disability requiring some help; mRS4, moderately severe dis-
ability requiring significant help with activities of daily living;
mRS6, dead; no patients had mRS5). The numbers in the
plot give the number of patients in each mRS class by treat-
ment assignment.
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having a recurrent event was present in those patients who
were enrolled during the acute phase.
The results of this subgroup analysis may be compared
with previous studies of BP-lowering in acute ischemic
stroke, especially those from the ACCESS trial,15 which also
studied an oral ARA (candesartan) in patients with acute
ischemic stroke within 72 hours of onset. However, the trials
differed in several key respects: size (ACCESS was much
smaller with 339 patients); time to recruitment (ACCESS had
a mean time of 30 hours); BP inclusion criteria (ACCESS
only included patients with severely elevated BP and had
mean BP 189/99 mm Hg); presence of other antihypertensive
agents (patients in ACCESS were not using any other BP
drugs); stroke severity (the baseline severity is not reported in
the ACCESS article but it is likely that the strokes will have
been far more severe with significantly greater impairment);
location (patients in ACCESS came from Germany only);
length of treatment (comparison of candesartan with placebo
in ACCESS was only made for 7 days with patients in both
treatment groups receiving candesartan thereafter for 1 year);
effect of treatment on BP (candesartan did not alter BP in
ACCESS); and results (the primary outcome, disability at 3
months, in ACCESS was neutral, although treatment with
candesartan was associated with a significant reduction in a
secondary outcome, comprising the cumulative 12-month
mortality and vascular events).15
Taking the similarities and differences between ACCESS
and PRoFESS, the apparent discrepancies in their results may
simply reflect a false-positive finding in the small ACCESS
trial. Additionally, the failure to show beneficial effects of
telmisartan may reflect that patients had only mild hyperten-
sion and mild stroke. Nevertheless, this subgroup analysis of
PRoFESS is the first to our knowledge to test whether it is
safe for patients with acute mild stroke to have their BP
actively lowered. Because chronic lowering of BP reduces
stroke recurrence,23,24 the present results suggest it is safe to
start such treatment acutely, particularly if based on an
angiotensin-modifying drug. Further, it is possible that these
results can be extrapolated to patients with TIA for which no
trials have been performed to date and, possibly, none are likely.
Several caveats exist for this PRoFESS subgroup analysis.
First, the results come from a subgroup of patients entered
into a large secondary prevention trial such that patient
characteristics reflect the inclusion criteria for a study of
vascular prophylaxis rather than acute intervention. As a
result, the trial was not designed to explicitly test the effect of
lowering BP in acute stroke. Second, the inclusion criteria
included neurological stability, which is usually absent in
acute stroke, and means that no patients were recruited during
the hyperacute phase (6 hours of onset) of stroke. Third, the
sample size was too small to reliably detect the effects of
telmisartan on functional outcome or secondary prevention.
The ongoing SCAST trial (http://www.scast.no) of candesar-
tan in 2500 patients will extend the existing data from
ACCESS and PRoFESS on lowering BP in acute ischemic
stroke with ARA. Other large trials are also assessing the
management of BP in acute stroke, including ENOS
Table 3. Cumulative Outcome and Safety at Days 7, 30, and
90 After Enrollment
Telmisartan
(n647)
Placebo
(n713) OR (95% CI)
7 Days
Dropouts (%)* 0 (0.0) 1 (0.14) …
Hemorrhagic
transformation (%)
0 (0.0) 3 (0.42) …
Cerebral edema (%) 0 (0.0) 0 (0.0) …
Stroke recurrence (%) 4 (0.62) 5 (0.70) 0.88 (0.24, 3.31)
MI (%) 1 (0.15) 0 (0.0) …
Combined vascular (%) 5 (0.77) 6 (0.84) 0.95 (0.28, 3.16)
Death (%) 0 (0.0) 1 (0.14) …
SAE (%) 12 (1.85) 10 (1.40) 1.37 (0.59, 3.21)
30 Days
Dropouts (%)† 4 (0.62 2 (0.28) 3.98 (0.52, 30.2)
mRS (mean, SD) 1.3 (1.1) 1.3 (1.1) …
mRS 0–1 vs 2–6 (%)† 401 (64.5) 452 (65.7) 1.00 (0.77, 1.29)
Stroke recurrence (%) 13 (2.01) 8 (1.12) 1.89 (0.77, 4.62)
MI (%) 2 (0.31) 0 (0.0) …
Combined vascular (%) 17 (2.63) 10 (1.40) 2.07 (0.93, 4.63)
Death (%) 4 (0.62) 2 (0.28) …
SAE (%) 29 (4.48) 25 (3.51) 1.30 (0.75, 2.25)
Mini-Mental State
Examination 30 (%)
190 (32.0) 207 (31.7) 1.02 (0.80, 1.31)
90 Days
Dropouts (%)* 6 (0.93) 6 (0.84) 1.25 (0.36, 4.36)
Stroke recurrence (%) 17 (2.6) 14 (2.0) 1.40 (0.68, 2.89)
MI (%) 3 (0.5) 1 (0.1) …
Combined vascular (%) 23 (3.6) 19 (2.7) 1.48 (0.78, 2.79)
Death (%) 5 (0.77) 6 (0.84) 1.05 (0.27, 4.04)
SAE (%) 50 (7.73) 39 (5.47) 1.43 (0.93, 2.22)
N (%) or mean (SD) with OR (95% CI). Comparison by binary logistic
regression or multiple regression (continuous variables).
SAE indicates serious adverse events.
*Dropouts are patients lost to follow-up at the time point.
†Patients with no day 30 outcome data were excluded.
Figure 2. Ordinal stroke (recurrence and severity) at day 90,
comparison by Mann–Whitney U test, P0.42 (note: the majority
of patients who did not have an event are not shown, and 3
patients with a recurrent stroke did not have a mRS recorded;
the numbers of patients with each outcome are shown).
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(n5000)3 in mixed ischemia/hemorrhage and INTERACT 2
(n3000) in intracerebral hemorrhage.25
In summary, this subgroup analysis of the PRoFESS trial
was neutral and did not identify any apparent beneficial or
hazardous effects of telmisartan on functional outcome in
patients with acute mild stroke. Nevertheless, the CI are wide
and antihypertensive treatment might be beneficial or hazard-
ous. The findings are relevant to patients with mild stroke
(and possibly TIA) but do not apply to patients with moderate
to severe stroke because no such patients were included. Several
ongoing large trials are addressing this latter question, and the
Cochrane Blood Pressure in Acute Stroke Collaboration system-
atic reviews4,5 will be updated to include the results of all of
these. In the meantime, guidelines (such as those from the
European Stroke Organisation26) should not be changed until the
results of these large randomized trials become available.
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